Isoprenoid metabolism and the pleiotropic effects of statins

Current Atherosclerosis Reports

Volumn 5, Issue 5, 2003, Pages 372-378

  Laufs, Ulrich ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPOPHILICITY; METABOLIC INHIBITION; METABOLISM; MUSCLE DISEASE; NONHUMAN; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; STROKE; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 0346278773     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0008-z     Document Type: Review

References (59)

1. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2001, 10:143-148.
2. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002, 97:105-116.
3. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003, 24:225-248.
4. Libby P, Aikawa M: Mechanisms of plaque stabilization with statins. Am J Cardiol 2003, 20:4B-8B.
5. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207-213.
6. Wassmann S, Laufs U, Baumer AT, et al.: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001, 59:646-654.
7. Wassmann S, Laufs U, Muller K, et al.: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002, 22:300-305.
8. Takemoto M, Node K, Nakagami H, et al.: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001, 108:1429-1437.
9. Laufs U, Kilter II, Konkol C, et al.: Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002, 53:911-920.
10. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
11. Laufs U, Liao JK: Targeting Rho in cardiovascular disease. Circ Res 2000, 87:526-528.
12. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266-24271.
13. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
14. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024-1028.
15. Smith SC Jr, Blair SN, Bonow RO, et al.: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001, 38:1581-1583.
16. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
17. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
18. Scandinavian Simvastatin Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
19. Knatterud GL, Rosenberg Y, Campeau L, et al.: Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000, 102:157-165.
20. Heart Protection Study Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
21. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
22. Packard CJ: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
23. Pekkanen J, Linn S, Heiss G, et al.: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease [see comments]. N Engl J Med 1990, 322:1700-1707.
24. Buchwald H, Varco RL, Boen JR, et al.: Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998, 158:1253-1261.
25. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
26. John S, Delles C, Jacobi J, et al.: Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001, 37:1351-1358.
27. Tsunekawa T, Hayashi T, Kano H, et al.: Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001, 104:376-379.
28. Laufs U, Wassmann S, Hilgers S, et al.: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001, 88:1306-1307.
29. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999, 33:234-241.
30. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
31. Masumoto A, Hirooka Y, Hironaga K, et al.: Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001, 88:1291-1294.
32. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452.
33. Thomas M, Mann J: Increased thrombotic vascular events after change of statin. Lancet 1998, 352:1830-1831.
34. Aikawa M, Rabkin E, Sugiyama S, et al.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.
35. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:1452-1458.
36. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
37. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
38. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
39. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
40. Southworth MR, Mauro VF: The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 1997, 31:489-491.
41. Goldberg R, Roth D: Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996, 62:1559-1564.
42. Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
43. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353:983-984.
44. Vaughan CJ: Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am J Cardiol 2003, 91:23B-29B.
45. Byington RP, Davis BR, Plehn JF, et al.: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001, 103:387-392.
46. Klungel OH, Heckbert SR, de Boer A, et al.: Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002, 36:751-757.
47. Endres M, Laufs U, Huang Z, et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998, 95:8880-8885.
48. Laufs U, Liao JK: Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 2003, 23:156-157.
49. Williams JK, Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31:684-691.
50. Reihner E, Rudling M, Stahlberg D, et al.: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990, 323:224-228.
51. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994, 73:3D-11D.
52. McTaggart F, Buckett L, Davidson R, et al.: Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87:28B-32B.
53. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T: Statin-stimulated nitric oxide release from endothelium. Med Sci Monit 2001, 7:622-627.
54. Laufs U, Gertz K, Dirnagl U, et al.: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002, 942:23-30.
55. Corsini A, Bellosta S, Baetta R, et al.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
56. Trauner M, Boyer JL: Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003, 83:633-671.
57. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681-1690.
58. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105:310-315.
59. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.